Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. More Details
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Micro-X's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MX1 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MX1's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: MX1 exceeded the Australian Medical Equipment industry which returned -9% over the past year.
Return vs Market: MX1 exceeded the Australian Market which returned -2.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Micro-X's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?
1 month ago | Simply Wall StHave Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?
1 month ago | Simply Wall StMicro-X Limited's (ASX:MX1) Shift From Loss To Profit
Is Micro-X undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MX1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MX1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MX1 is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.
PE vs Market: MX1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MX1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MX1 is overvalued based on its PB Ratio (9.1x) compared to the AU Medical Equipment industry average (7.2x).
How is Micro-X forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MX1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MX1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MX1's is expected to become profitable in the next 3 years.
Revenue vs Market: MX1's revenue (67% per year) is forecast to grow faster than the Australian market (5.1% per year).
High Growth Revenue: MX1's revenue (67% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MX1's Return on Equity is forecast to be very high in 3 years time (54%).
How has Micro-X performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MX1 is currently unprofitable.
Growing Profit Margin: MX1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MX1 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.6% per year.
Accelerating Growth: Unable to compare MX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MX1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (41.9%).
Return on Equity
High ROE: MX1 has a negative Return on Equity (-67.55%), as it is currently unprofitable.
How is Micro-X's financial position?
Financial Position Analysis
Short Term Liabilities: MX1's short term assets (A$25.4M) exceed its short term liabilities (A$8.7M).
Long Term Liabilities: MX1's short term assets (A$25.4M) exceed its long term liabilities (A$10.1M).
Debt to Equity History and Analysis
Debt Level: MX1's debt to equity ratio (51.8%) is considered high.
Reducing Debt: MX1 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MX1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MX1 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 7.9% each year.
What is Micro-X current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MX1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MX1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MX1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MX1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Peter Robin Rowland, BSc., MBA, MIET, CEng, FAICD, serves as Managing Director, Executive Director and Chief Executive Officer of Micro-X Limited. Mr. Rowland is a laser industry veteran with experienc...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD268.58K) is about average for companies of similar size in the Australian market ($USD294.50K).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
|MD, CEO & Director||6.33yrs||AU$349.53k||3.6% |
|Non-Executive Director||no data||no data||0.017% |
|Independent Non-Executive Director||4.08yrs||AU$61.98k||0.018% |
|Non-Executive Director||0.75yr||AU$15.50k||0.070% |
|Independent Non Executive Chairman||5.42yrs||AU$77.50k||2.16% |
|Independent Non-Executive Director||5.42yrs||AU$55.00k||0.13% |
Experienced Board: MX1's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.8%.
Micro-X Limited's company bio, employee growth, exchange listings and data sources
- Name: Micro-X Limited
- Ticker: MX1
- Exchange: ASX
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$138.389m
- Shares outstanding: 359.45m
- Website: https://www.micro-x.com
- Micro-X Limited
- A14, 6 MAB Eastern Promenade
- 1284 South Road
- South Australia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MX1||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
|MX1||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2015|
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The com...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/19 07:03|
|End of Day Share Price||2021/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.